Orbis Kicks Off 2025 with €90M Series A Funding in Fierce Biotech Fundraising Tracker

Orbis Series A Funding:
Orbis has secured €90 million in a Series A funding round, marking a significant start to 2025 in the biotech fundraising landscape3 5.

Fierce Biotech Fundraising Tracker:
The tracker is a comprehensive record of significant venture capital investments in the biotech industry, with a focus on rounds exceeding $50 million in 2024 and continuing into 20251 2.

Industry Trends:
The biotech industry is seeing a renewed interest in various therapeutic areas, including mRNA delivery, gene editing, and antibody-drug conjugates, as evidenced by significant funding rounds in 20241 2 4.

Investment Highlights:
Notable 2024 funding rounds include Formation Bio's $372 million Series D, Exsilio Therapeutics' $82 million Series A, and BioAge Labs' $170 million Series D, indicating strong investor confidence in innovative biotech companies1 2.

2025 Outlook:
The new year is expected to see continued investment in biotech, with venture capital firms like Arch Venture Partners closing funds exceeding $3 billion to support biopharma startups4.